Caregivers should verify coverage, supervised training, and MRI follow-up before giving Leqembi IQLIK at home. IQLIK is a weekly subcutaneous lecanemab-irmb autoinjector for adults with early Alzheimer's disease. Training covers the device only, and home use starts after supervised doses. Ongoing brain scans and symptom checks continue after home dosing begins.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who qualifies to start?
- How does home injection training work?
- What help does the Companion program offer?
- What follow-up must continue at home?
Who qualifies to start?
Treatment is limited to mild cognitive impairment or mild dementia due to Alzheimer's with amyloid-beta confirmed by PET scan or spinal-fluid testing, as Drugs.com summarizes in its FDA approval history. Caregivers should confirm the diagnosis and test result are documented before scheduling training. Eisai reports FDA clearance for maintenance dosing in August 2025 and for initiation dosing on July 13, 2026.
The initiation regimen is 500 mg once weekly as two consecutive 250-mg injections, each given in about 15 seconds. Patients may switch between IV and subcutaneous routes when the prescriber directs it. Ask the clinic to confirm in writing:.
- early Alzheimer's stage and amyloid result on file
- prescribed start dose and route
- specialty pharmacy coverage and delivery date
How does home injection training work?
Patients or caregivers may give IQLIK at home only after two consecutive subcutaneous doses under provider supervision with a finding of safe self-administration, as Haymarket Neurology Advisor reports in its Eisai and Biogen summary. Use those visits to practice handling, timing, and disposal. Training focuses on correct autoinjector use, not on broader Alzheimer's care. Bring the person who will give most injections.
Ask for a return demonstration and written steps for missed doses, bruising, and device failure. Confirm injection sites before leaving the clinic. Use abdomen or upper thigh for self-injection. Use upper arm only when another person gives the shot.
What help does the Companion program offer?
Eisai and Biogen's LEQEMBI Companion program provides in-person or virtual Nurse Educator teaching on the device only, as Eisai describes in its program notice. It also offers an injection-tracking app and welcome kit. The same program offers insurance and financial-support help through specialty pharmacy channels. Caregivers should ask which pharmacy will fill IQLIK and who submits prior authorization.
Keep the support phone number with the medication. Use the app to log date, dose, site, and any fever, headache, confusion, or bleeding. Bring that log to each visit. It helps the care team spot patterns early.
What follow-up must continue at home?
The FDA label carries a boxed warning for amyloid-related imaging abnormalities with swelling or bleeding, requires a recent baseline brain MRI plus scans after 1, 2, 3, and 6 months, and calls for ApoE ε4 testing to inform risk, according to the prescribing information. Practical Neurology notes caregivers should keep scheduled MRI and symptom follow-up even after home dosing begins. Do not skip scans because injections feel routine.
Watch for headache, dizziness, nausea, vision changes, confusion, or trouble walking. Seek same-day care for sudden or severe symptoms. Keep MRI dates on the same calendar as injection days.
You Might Also Like
- Leqembi IQLIK Injection Training for Alzheimer’s Caregivers: Who May Qualify and Who Needs Further Review
- Leqembi IQLIK Injection Training for Alzheimer’s Caregivers: What Patients and Caregivers Need to Prepare
- Leqembi IQLIK Injection Training for Alzheimer’s Caregivers: Safety Warnings, Monitoring, and When to Call
